For questions about BMS medicines during this time, please call 1-800-721-8909.

This website is best viewed using the
horizontal display on your tablet device.

This website is best viewed using the
vertical display on your mobile device.

Target the immune system1

Targeting of normal cells can also occur.2,3
OPDIVO helps existing T cells discover the
tumor by blocking PD-1.4-9

YERVOY helps activate and proliferate T cells by blocking CTLA-4, and also reduces Treg function.1,4,5

Select a patient population below to review trial
results, or view available Bristol Myers Squibb
resources

Metastatic Melanoma

Checkmate 067 clinical trial

See Results
Adjuvant Treatment
of Melanoma

Checkmate 238 clinical trial

See Results
Resources

Clinical trial presentation
decks, education, and
patient support materials

Download Resources
References
  1. OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company.
  2. Metro G, Ricciuti B, Brambilla M, et al. The safety of nivolumab for the treatment of advanced non-small cell lung cancer. Expert Opin Drug Saf. 2017;16(1):101-109.
  3. Byrne EH, Fisher DE. Immune and molecular correlates in melanoma treated with immune checkpoint blockade. Cancer. 2017;123(S11):2143-2153.
  4. Weber JS, Hamid O, Chasalow SD, et al. Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma. J Immunother. 2012;35(1):89-97.
  5. Ansell SM, Hurvitz SA, Koenig PA, et al. Phase I study of ipilimumab, an anti—CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clin Cancer Res. 2009;15(20):6446-6453.
  6. Farber DL, Yudanin NA, Restifo NP. Human memory T cells: generation, compartmentalization, and homeostasis. Nat Rev Immunol. 2014;14(1):24-35.
  7. Felix J, Lambert J, Roelens M, et al. Ipilimumab reshapes T cell memory subsets in melanoma patients with clinical response. Oncoimmunology. 2016;5(7):e1136045.
  8. Pedicord VA, Montalvo W, Leiner IM, Allison JP. Single dose anti—CTLA-4 enhances CD8+ T-cell memory formation, function, and maintenance. Proc Natl Acad Sci U S A. 2011;108(1):266-271.
  9. Pico de Coaña Y, Wolodarski M, Poschke I, et al. Ipilimumab treatment decreases monocytic MDSCs and increases CD8 effector memory T cells in long-term survivors with advanced melanoma. Oncotarget. 2017;8(13):21539-21553.